ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Autoimmune Diseases
Alzheimer Disease
Amyotrophic Lateral Sclerosis

Multiple Sclerosis (MS) trials near Cleveland, OH, USA:

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...

Enrolling
Secondary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Biological: Best Available Therapy (BAT)

Phase 3

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)

Cleveland, Ohio, United States and 19 other locations

main endpoint. Safety, tolerability, and efficacy are secondary endpoints. Approximately 20 participants with relapsing or progressive forms of MS...

Begins enrollment in 4 months
Multiple Sclerosis (MS) - Relapsing-remitting
Multiple Sclerosis (MS) Primary Progressive
Drug: Remibrutinib (Open Label)

Phase 2

Moein Amin

Cleveland, Ohio, United States

In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...

Enrolling
Relapsing Forms of Multiple Sclerosis
Drug: BIIB091
Drug: DRF

Phase 2

Biogen
Biogen

Cleveland, Ohio, United States and 76 other locations

The purpose of this research is to support the clinical value of the Cionic Neural Sleeve for individuals diagnosed with multiple sclerosis...

Enrolling
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Behavioral: Walking Program
Device: Cionic Neural Sleeve NS-100
Cionic

Cleveland, Ohio, United States

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis
Drug: Ocrelizumab
Drug: Fingolimod

Phase 3

Roche
Roche

Cleveland, Ohio, United States and 105 other locations

New

clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple...

Begins enrollment in 1 month
Multiple Sclerosis
Biological: AZD0120 - Regimen 2
Biological: AZD0120 - Regimen 1

Phase 1

AstraZeneca
AstraZeneca

Cleveland, Ohio, United States and 8 other locations

The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).

Enrolling
B-cell Mediated Autoimmune Disorders
Drug: Azercabtagene zapreleucel (azer-cel)

Phase 1

TG Therapeutics
TG Therapeutics

Cleveland, Ohio, United States and 6 other locations

Locations recently updated

This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥1...

Enrolling
Secondary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Placebo

Phase 3

Sanofi
Sanofi

Cleveland, Ohio, United States and 352 other locations

) neo-antigen in subjects with relapsing multiple sclerosis (RMS).COVID-19 sub-study:The purpose of this research sub-study is to e...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

Phase 3

Novartis
Novartis

Cleveland, Ohio, United States and 299 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems